Journal article
Cardiovascular risk assessment and treatment in systemic lupus erythematosus
Best practice & research. Clinical rheumatology, v 23(4), pp 481-494
01 Aug 2009
PMID: 19591779
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
With improved treatment modalities and survival rates, patients with systemic lupus erythematosus live longer and their co-morbidities have become more apparent. Of great concern is cardiovascular disease, which has become a leading cause of death. Lupus patients prematurely develop atherosclerosis, which likely arises from an interaction among traditional cardiovascular risk factors, factors specific to lupus itself and inflammatory mediators. Despite these findings, lupus patients are not always adequately evaluated for traditional risk factors, many of which are treatable and reversible. We propose that lupus patients be assessed and managed regarding cardiovascular risk factors in the same manner as patients with known cardiovascular disease. As a result, preventive cardiology should be considered an essential component of the care for patients with lupus.
Metrics
Details
- Title
- Cardiovascular risk assessment and treatment in systemic lupus erythematosus
- Creators
- Jennifer R. Elliott - University of PittsburghSusan Manzi - University of Pittsburgh
- Publication Details
- Best practice & research. Clinical rheumatology, v 23(4), pp 481-494
- Publisher
- Elsevier
- Number of pages
- 14
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- General Internal Medicine
- Web of Science ID
- WOS:000268741600004
- Scopus ID
- 2-s2.0-67649814984
- Other Identifier
- 991021933902004721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Rheumatology